Despite decades of research, we know very little of how cancer drug resistance can arise in acute myeloid leukaemia (AML), and approaches to overcome chemoresistance are important for curative therapies. Each year in the UK there are over 2,600 AML patient deaths. AML is currently incurable and for the majority of AML patient’s (≥65 years of age) 5-year survival is <20%, with little improvement in these figures observed in the last two decades. Chemoresistance is a major contributing factor towards treatment failure, disease relapse and death in AML patients (Burnett et al., 2012). The involvement of the bone marrow microenvironment (BMME) in the development of chemoresistance is well documented in AML, with mounting evidence suggesting that AML-macrophage (Mφ cross-talk influences the Mφ phenotype, which in turn blunts the response of AML blasts towards chemotherapeutics.
|Short title||Macrophage mediated chemoresistance in Acute Myeloid Leukaemia|
|Effective start/end date||1/07/21 → 31/08/21|
- British Society for Haemotology: £17,999.00
UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This project contributes towards the following SDG(s):
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.